Bexorg received up to $28.3 million from ARPA-H to extend its BrainEx ex vivo brain perfusion platform from 24 hours to as long as two weeks across a three-phase, 36-month program. The extended window would permit repeated dosing and sustained drug exposure in intact human brain tissue, capturing pharmacological mechanisms that only emerge beyond a single day. Longitudinal multi-omics datasets generated this way are intended to inform dosing strategy, biomarker selection and trial design for Alzheimer's disease and other central nervous system conditions.
Key Points
- ARPA-H funds extension of brain perfusion from 24 hours to two weeks
- Enables repeated dosing and longitudinal human brain pharmacology studies
- Prior BrainEx data supported Biohaven's BHV-8100 IND filing
Longevity Analysis
Neurodegenerative drug development has long depended on animal models and post-mortem tissue, neither of which captures how a living human brain metabolizes, clears and responds to sustained compound exposure. Maintaining perfusion — the continuous delivery of oxygen and substrate that keeps neural tissue functionally intact — for two weeks rather than one day shifts the question from whether tissue survives to how it adapts, repairs and signals over a therapeutically meaningful interval. For interventions aimed at preserving cognition across decades, the ability to read drug response and biomarker trajectories directly from human neural tissue narrows the gap between mechanistic hypothesis and clinical outcome.
Original published by LT Wire.